[Ip-health] Statement by MSF on the Official Release of the Full Text of the Trans-Pacific Partnership Trade Agreement

Michelle French Michelle.French at newyork.msf.org
Thu Nov 5 14:27:04 PST 2015


5 November, 2015

MSF responds to the official release of the full text of the Trans-Pacific 
Partnership trade agreement
The Trans-Pacific Partnership (TPP) is a trade agreement negotiated 
between the U.S. and eleven other Pacific Rim nations: Australia, Brunei 
Darussalam, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, 
Singapore and Vietnam. After more than five years of negotiations 
conducted in secret without the opportunity for public review, the agreed 
text, which will now be submitted to national processes for final 
signature and ratification, has been officially and publicly released. 
 Doctors Without Borders/Médecins Sans Frontières (MSF) remains extremely 
concerned about the inclusion of dangerous provisions that would dismantle 
public health safeguards enshrined in international law and restrict 
access to price-lowering generic medicines for millions of people.
Statement by Judit Rius Sanjuan, U.S. manager and legal policy advisor for 
MSF’s Access Campaign:
"MSF remains gravely concerned about the effects that the Trans-Pacific 
Partnership trade deal will have on access to affordable medicines for 
millions of people, if it is enacted. Today’s official release of the 
agreed TPP text confirms that the deal will further delay price-lowering 
generic competition by extending and strengthening monopoly market 
protections for pharmaceutical companies.
The TPP is a bad deal for medicine: it’s bad for humanitarian medical 
treatment providers such as MSF, and it’s bad for people who need access 
to affordable medicines around the world, including in the United States.
At a time when the high price of life-saving medicines and vaccines is 
increasingly recognized as a barrier to effective medical care, it is very 
concerning to see that the U.S. government and pharmaceutical companies 
have succeeded in locking in rules that will keep medicine prices high for 
longer and limit the tools that governments and civil society have to try 
to increase generic competition.
For example, if enacted, the TPP will not allow national regulatory 
authorities to use existing data that demonstrates a biological product’s 
safety and efficacy to authorize the sale of competitor products, even in 
the absence of patents.  The TPP would also force governments to extend 
existing patent monopolies beyond current 20-year terms at the request of 
pharmaceutical companies, and to redefine what type of medicine deserves a 
patent, including mandating the granting of new patents for modifications 
of existing medicines.
The provisions in the TPP text will not only raise the price of medicines 
and cause unnecessary suffering, but they also represent a complete 
departure from the U.S. government’s previous commitments to global 
health, including safeguards included in the U.S.’s 2007 ‘New Trade 
It is not too late to prevent further restrictions on access to affordable 
medicines in the TPP. As the text now goes to national legislatures for 
final approval, we urge all TPP governments to carefully consider whether 
the agreed TPP text reflects the direction they want to take on access to 
affordable medicines and promotion of biomedical innovation; if it does 
not, the TPP should be modified or rejected.”


Michelle French
Sr. Communications Manager, MSF Access Campaign
Doctors Without Borders\Médecins Sans Frontières (MSF)
Office: +1.212.763.5735 | Mobile: +1.646.552.4600
michelle.french at newyork.msf.org | Skype: michellejfrench
www.msfaccess.org | twitter.com/MSF_access | www.facebook.com/MSFaccess

More information about the Ip-health mailing list